LLY's Olumiant Gets FDA Nod for Expanded Use in Pediatric Hair LossZacks Investment Research • 09/28/26
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should KnowZacks Investment Research • 09/28/26
Eli Lilly Wavered Over the Last Month: One of Wall Street's Biggest Banks Says 35% Gains Still to Come24/7 Wall Street • 09/28/26
Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICsPRNewsWire • 09/28/26
Eli Lilly Just Won FDA Approval for a Once Weekly Insulin and the Stock Is Knocking on $1,20024/7 Wall Street • 09/27/26
FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areataPRNewsWire • 09/25/26
Eli Lilly Vs. Pfizer in 2027: One Is a Much Better Place to Park Your Pharmaceutical Capital Next Year24/7 Wall Street • 09/23/26